Patricio Eduardo Yanez

机构：Universidad de La Frontera · ORCID：0009-0008-5845-831X

发表论文 31 篇 · 总被引 6645 次 · h-index 16

代表论文

• First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial (2021 · The Lancet · 被引 3109)
• The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer (2021 · Nature · 被引 717)
• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 698)
• Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial (2023 · The Lancet · 被引 514)
• Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer (2022 · Nature · 被引 455)
• Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study (2023 · The Lancet Oncology · 被引 377)